Emodepside Phase II Trial for Treatment of Onchocerciasis

Onchocerciasis Clinical Trial

Official title:
A Phase-II, Randomised, Double-blind, Parallel-group Trial to Investigate Emodepside (BAY 44-4400) in Subjects With Onchocerca Volvulus Infection, Comprising: Part 1 to Investigate Safety, Tolerability, Pharmacodynamics, Pharmacokinetics and Dose-Response Relationship for Efficacy (Proof-of-Concept); Part 2 to Investigate Efficacy of Selected Doses, Safety, Tolerability and Pharmacokinetics

Status Active, not recruiting

Clinical Trial Summary

The trial evaluates safety, tolerability, pharmacodynamics, pharmacokinetics, dose-response, and efficacy of emodepside tablets, administrated as a range of dose regimens, in adults infected with Onchocerca Volvulus.

Clinical Trial Description

There is an urgent need for a macrofilaricidal drug targeting the adult stage of Onchocerca volvulus, which could be used in individual case management and, after appropriate testing, as an alternative drug to ivermectin in Mass Drug Administration (MDA) programs. Emodepside is a promising drug candidate to kill the adult and sexually mature Onchocerca volvulus. Emodepside was shown to be macrofilaricidal and microfilaricidal against a variety of filarial nematodes in non-clinical studies, and is a registered drug for animal health, commercialized by Bayer AG under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). Three Phase I trials of emodepside with single or multiple doses of emodepside have been conducted in healthy Caucasian men. The results are encouraging and support continuation of the clinical development programme of emodepside as treatment for onchocerciasis. One of these trials also enabled the selection of a field-adapted tablet formulation, suitable for use in countries endemic for onchocerciasis. The present trial is designed in a stepwise approach starting with a proof of concept part, which is further subdivided in steps to investigate the safety, tolerability and pharmacokinetics of emodepside in the target population - Part 0 (pilot group), followed by investigations of the safety of emodepside in low and high-microfilaria carriers - Part 1a, and the dose-response relationship for efficacy of emodepside compared to placebo in microfilaria-positive patients - Part 1b. This approach allows to maximize the information regarding the safety of emodepside in the target population and to establish a dose range, in which emodepside is efficacious. Based on the information obtained from Parts 0 and 1, up to two efficacious dose regimens will be selected to carry forward into the confirmatory, active-controlled Part 2 of the trial, which will investigate the superiority of emodepside over ivermectin assessed using a clinically relevant endpoint, i.e. long-term absence of microfilariae at month 24. ;

Study Design

Related Conditions & MeSH terms

Onchocerciasis

Clinical Trial Details

NCT number	NCT05180461
Study type	Interventional
Source	Drugs for Neglected Diseases
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	August 30, 2021
Completion date	October 2, 2026

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00300768` - Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection	Phase 2
Not yet recruiting	`NCT04035174` - Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa	N/A
Recruiting	`NCT03653975` - Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
Completed	`NCT03052998` - Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy	Phase 4
Recruiting	`NCT04311671` - Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole	Phase 3
Active, not recruiting	`NCT03876262` - Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis	Phase 3
Terminated	`NCT04913610` - Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection	Phase 2
Completed	`NCT03962062` - A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years	Phase 1
Completed	`NCT01905436` - Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Recruiting	`NCT00001230` - Host Response to Infection and Treatment in Filarial Diseases
Completed	`NCT05750043` - Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan
Completed	`NCT05749653` - Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area	N/A
Completed	`NCT02078024` - Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana	Phase 3
Completed	`NCT00127504` - Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness	Phase 2
Completed	`NCT03131401` - Prevalence of LF Infection in Districts Not Included in LF Control Activities
Not yet recruiting	`NCT06070116` - Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis	Phase 2
Completed	`NCT02032043` - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
Completed	`NCT04188301` - Safety and Efficacy of IDA for Onchocerciasis	Phase 2
Terminated	`NCT05084560` - Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug	Phase 1
Completed	`NCT03517462` - Ocular Changes After Ivermectin - (DOLF IVM/Oncho)	N/A